## **1** Usefulness of aortic valve calcification in patients with low flow aortic stenosis

3 4 5 6 7	Nils Sofus Borg Mogensen, MD <sup>1,2,3</sup> , Jordi Sanchez Dahl MD, PhD, DMSCi <sup>1,3</sup> , Mulham Ali, MD <sup>1</sup> , Mohamed-Salah Annabi, MD, MSc <sup>2</sup> , Amal Haujir, MD <sup>1,2</sup> , Andréanne Powers, MD <sup>2</sup> , Rasmus Carter-Storch, MD, PhD <sup>1,3</sup> , Jasmine Grenier-Delaney, MSc <sup>2</sup> , Jacob Eifer Møller, MD, PhD, DMSCi <sup>1,4</sup> , Kristian Altern Øvrehus MD, PhD <sup>1</sup> , Philippe Pibarot DVM, PhD <sup>2</sup> , Marie-Annick Clavel DVM, PhD <sup>1,2</sup>
8	
9	
10	<sup>1</sup> Department of Cardiology, Odense University Hospital, Odense, Denmark.
11 12	<sup>2</sup> Institut Universitaire de Cardiologie et de Pneumologie de Québec (Québec Heart and Lung Institute), Laval University, Québec, Québec, Canada.
13	<sup>3</sup> Clinical Institute, University of Southern Denmark, Odense, Denmark.
14 15	<sup>4</sup> Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
16	
17	Running title: AVC in low flow AS
18	
19	Addresses for correspondence:
20	Dr Marie-Annick Clavel, Institut universitaire de cardiologie et de pneumologie de
21	Québec, 2725 Chemin Sainte-Foy, Québec city, Québec, Canada, G1V-4G5.
22	Telephone number: 418-656-8711 (ext. 2678)
23	E-mail address: Marie-Annick.Clavel@criucpq.ulaval.ca.
24	
25	Words count: 4675
26	
27	Disclosure:
28 29 30	Dr Clavel received funding from Edwards Lifesciences for CT core laboratory analyses and Research grant from Medtronic, Edwards Lifesciences and Pi-Cardia with no direct personal compensation. Dr Pibarot received funding from Edwards Lifesciences and

- 31 Medtronic for echocardiography core laboratory analyses with no direct personal
- 32 compensation. The remaining authors have nothing to disclose.
- 33

#### 34 Source of Funding:

- 35 This work was supported by research grants from Canadian Institutes for Health
- Research, the Institut de cardiologie et de Pneumologie de Québec, the Region of
- 37 Southern Denmark and the University of Southern Denmark.
- 38

### 39 ABSTRACT

40	Background: Aortic valve calcification (AVC) has been shown to be a powerful
41	assessment of aortic stenosis severity (AS) and predictor of adverse outcome. However,
42	its accuracy in patients with low-flow AS has not yet been proven.
43	<b>Objectives:</b> To assess the predictive value of AVC in patients classical (CLF, i.e. low left
44	ventricular ejection fraction [LVEF]) or paradoxical (PLF, i.e. low flow preserved LVEF)
45	AS patients.
46	Methods: We prospectively include 641 patients, 319 (49.8%) with CLF-AS and 322
47	(50.2%) with PLF-AS who underwent Doppler-echocardiography and multidetector
48	computed tomography. AVCratio was calculated as AVC divided by the sex-specific
49	AVC threshold for AS-severity; AVC score ≥2,000 AU in males, and ≥1,200 AU in
50	females. The primary endpoint of the study was all-cause mortality regardless of
51	treatment.
52	<b>Results:</b> During a median follow-up of 4.9 (4.3-5.9) years there were 265 deaths. After
53	comprehensive adjustment, AVCratio was associated with all-cause mortality in CLF-AS
54	(aHR=1.25 [1.01-1.56]; p<0.05) and PLF-AS (aHR=1.51[1.14-2.00]; p=0.004) patients.
55	There was an interaction (p=0.001) between AVC and AS flow pattern (i.e. CLF vs. PLF)
56	with regard to the prediction of mortality. The best AVCratio threshold to predict
57	mortality was different in CLF-AS (AVCratio≥0.7) and PLF-AS (AVCratio≥1) patients.
58	After comprehensive analysis, AVCratio as a dichotomic variable was associated with
59	all-cause mortality in all groups ( $p \le 0.001$ ). The addition of AVCratio to the models
60	improved all model's predictive value (all net reclassification index >18%; all p $\leq$ 0.05).

61	Co	nclusion: In patients with CLF or PLF AS, AVC is a major predictor of mortality.
62	Th	us, AVC should be used in low flow patients to stratify risk. Importantly, in patients
63	wit	th reduced LVEF, a non-severe AS (i.e. AVC 70% of severe) could be associated with
64	red	luce survival.
65		
66	Cli	inical Perspective
67	Wł	nat is new?
68	-	Aortic valve calcification is a powerful predictor of outcome in patients with low
69		ejection fraction aortic stenosis and in patients with low-flow despite normal ejection
70		fraction aortic stenosis.
71	-	In patient with low ejection fraction aortic stenosis, a non-severe calcification
72		(AVCratio=0.7) is associated with increased mortality. An AVCratio of 0.7
73		correspond to an AVC of 840AU in female patients and 1,400AU in male patients.
74	Wł	nat are the clinical implications?
75	-	AVC should be used in low ejection fraction and low flow patients to assess aortic
76		stenosis severity and stratify risk.
77	-	A severe AVC, in patient with low-flow preserved ejection fraction, could help in
78		clinical decision making.
79	-	A moderate-to-severe AVC (i.e. AVCratio>0.7), in patients with low ejection
80		fraction, is detrimental and may be used to refine clinical decision making.
81		

# 82 Introduction

83	Evaluation of aortic stenosis (AS) severity is the cornerstone of the management of
84	patients with AS. Indeed, all the recommendations for intervention in the current
85	guidelines <sup>1, 2</sup> target patients with severe AS, except patients requiring non-aortic valve
86	related open-heart surgery; in this case, intervention on moderate AS may be considered.
87	Doppler-echocardiography is the gold standard to assess AS severity. When a peak aortic
88	jet velocity $\geq 4m/s$ or a mean gradient (MG) $\geq 40mmHg$ coexists with an aortic valve area
89	(AVA) $\leq 1$ cm <sup>2</sup> or an indexed AVA $\leq 0.6$ cm <sup>2</sup> /m <sup>2</sup> the diagnosis of severe AS is
90	straitghforward <sup>3</sup> . However, in up to 40% of the patients with AS, these parameters are
91	discordant with, most of the time, a low velocity/MG despite a small AVA <sup>4</sup> . This
92	discordance is often associated with a low flow state that is defined by a decreased left
93	ventricular ejection fraction (LVEF<50%) in Classical Low Flow patients (CLF) or,
94	when LVEF is preserved, by a low stroke volume index (SVi≤35ml/m <sup>2</sup> ) in Paradoxical
95	Low Flow patients (PLF) <sup>1</sup> . In CLF patients, a dobutamine stress echocardiography is
96	recommended to assess the actual AS severity. However, this test is not always
97	performed, and when performed, often not conclusive as many patients do not respond
98	sufficiently to dobutamine to reach a normal flow <sup>5</sup> . Moreover, in patients with PLF,
99	dobutamine stress echocardiography is not recommended <sup>1</sup> .
100	The measurement of aortic valve calcification (AVC) by multidetector computed
101	tomography (MDCT) <sup>6</sup> is an alternative imaging modality to assess AS severity. Sex-
102	specific thresholds have been proposed to identify severe AS <sup>7</sup> and extensively validated,
103	especially against hard endpoints <sup>8-10</sup> , but mostly in patients with normal flow. In the

present study, we aimed to evaluate the impact of AVC in patients with CLF and PLFAS.

#### 106 Methods

- 107 We included patients aged  $\geq 18$  years with CLF (i.e. LVEF<50%) or PLF (i.e. SVi $\leq 35$
- $mL/m^2$ ) AS in prospective studies at Institut Universitaire de Cardiologie et de
- 109 Pneumologie de Quebec, Canada and Odense University Hospital, Denmark. Patients
- underwent concomitant (within 3 months) Doppler-echocardiography and computed
- tomography evaluation. Studies were accepted by local ethic committees and patients
- signed a written consent to participate.

#### 113 <u>Clinical data</u>

114 All clinical, echocardiographic and MDCT data were prospectively collected as part of

research protocols. Baseline clinical data included age, sex, body surface area (BSA),

116 NYHA functional class, diabetes, hypertension, atrial fibrillation, coronary artery disease

117 (CAD), and chronic kidney disease. The date of the transthoracic echocardiographic

118 examination was defined as the baseline visit.

#### 119 *Echocardiography*

Patients underwent a comprehensive transthoracic echocardiographic examination using commercially available ultrasound systems in accordance with the American Society of Echocardiography guidelines<sup>3, 11</sup>. Doppler values were calculated as the average of three cardiac cycles for patients with sinus rhythm and five cycles for atrial fibrillation. Left ventricular (LV) outflow tract diameter was measured in the parasternal long-axis view in early systole at the insertion of aortic valve leaflets. AVA was calculated by quantitative

126	Doppler ultrasound using the continuity equation. Peak flow velocity across the valve
127	was determined in the echocardiographic window where the highest velocity could be
128	recorded using continuous wave Doppler. Mean transvalvular gradient was estimated
129	using the modified Bernoulli equation. LVEF was determined by the Simpson biplane
130	method. LV stroke volume was calculated using pulsed-wave Doppler as the product of
131	the LV outflow area and LV outflow tract time velocity integral and indexed for BSA to
132	provide SVi.
133	Patients with LVEF<50% were considered with CLF-AS irrespective of SVi and patients
134	with LVEF $\geq$ 50% and SVi $\leq$ 35ml/m <sup>2</sup> were considered with PLF-AS.
135	Cardiac computer tomography
136	Patients underwent non-contrast MDCT scan with available scanner (SOMATOM Force,
137	SOMATON Definition, Siemens Medical Solution, Germany, and BRILLANCE iCT,
138	Philips, The Netherlands). Non-contrast-enhanced calcium scans were performed using a
139	prospective ECG gated scan at 60-80% of the QRS complex and with a tube voltage of
140	120 kV. The images were reconstructed with a slice thickness of 2.5- or $3$ -mm <sup>6</sup> .
141	Radiation expose was typically 1 millisievert. All calcium scoring assessments were
142	conducted using the same process, with dedicated software (Aquarius iNtuition, Tera
143	Recon, Inc., Foster City, California or Syngo Via, Siemens Healthineers, Munich,
144	Germany), by uniformly trained operators in a core laboratory (ValvulaR Multi-Modality
145	Imaging Core Laboratory (VarMI-CL) Quebec). AVC score was assessed by Agatston
146	method, expressed in arbitrary units (AU) <sup>12, 13</sup> . AVCratio was calculated as AVC divided
147	by the sex-specific AVC threshold for AS-severity; AVC score ≥2,000 AU in males, and

148  $\geq 1,200 \text{ AU}$  in females<sup>7, 8</sup>. Thus, an AVCratio  $\geq 1$  define a severe AS in both female and 149 male patients.

150 *Endpoints* 

151 The primary endpoint of the study was all-cause mortality regardless of treatment. The

secondary end-point was all-cause mortality in patients who did not receive AVR.

#### 153 <u>Statistical analysis</u>

154 Continuous variables were tested for normality with the Shapiro-Wilk test, the normally

distributed variables are presented as mean  $\pm$ SD and compared between groups using

156 Student's t-test. As AVC was not normally distributed, it is presented as median

157 (interquartile range) and compared between groups using the Kruskal-Wallis test.

158 Categorial variables are presented as number (percentage) and compared using Chi-

square or Fisher's exact tests, as appropriate. The best thresholds of AVCratio to predict

160 mortality was assessed by a penalized spline curve in each low flow AS pattern (i.e. CLF

and PLF). Survival rates were calculated using the Kaplan–Meier analysis, and univariate

and multivariate Cox proportional hazard regression (presented as adjusted hazard ratio:

163 aHR [95% confidence interval], p-value). All multivariate Cox model were adjusted for

the background model including age, sex, diabetes, hypertension, coronary artery disease,

renal failure, atrial fibrillation, New York Heart Association functional class, LVEF, and

166 AVR (as a dependent variable). Variables used in the background model were the

167 clinically relevant variables as well as variables significantly associated with mortality in

univariate analysis. To assess the additive value of AVCratio over the background model,

169 net reclassification index (NRI) was used.

- 170 All statistical analyses were performed with STATA/SE V.17.0 (StataCorp, Texas, USA)
- 171 software. A p-value<0.05 was considered statistically significant.

172 **Results** 

- 173 <u>Study population</u>
- We included 641 patients, 319 (49.8%) with CLF-AS and 322 (50.2%) with PLF-AS
- (Figure 1). Mean age of the patients was  $77.0 \pm 9.8$  years and 429 (67%) were male.
- 176 Patients with CLF-AS were older, more often male and had overall more comorbidities
- and more symptoms than patients with PLF-AS (Table 1). CLF-AS patients had similar
- 178 AVA with lower SVi, MG and peak aortic jet velocity but higher AVC than PLF-AS
- 179 patients.
- 180 As expected, CLF AS patients with higher AVCratio were older and had more severe AS
- 181 compared to CLF AS patients with low AVCratio (Table 2). As well, PLF AS patients
- 182 with higher AVCratio were older, more symptomatic and have more severe AS compared
- to PLF AS patients with low AVCratio (Table 2).
- 184 *Impact of AVC on overall mortality*
- 185 During a median follow-up of 4.9 (4.3-5.9) years there were 265 deaths. After adjustment
- by the background model AVCratio as a continuous variable (aHR=1.30 [1.09-1.54];
- p=0.003) was associated with all-cause mortality in the whole cohort, as well as in CLF-
- AS (aHR=1.25 [1.01-1.56]; p<0.05) and PLF-AS (aHR=1.51[1.14-2.00]; p=0.004)
- 189 patients.

190	Compared	l to bac	ckground	models,	the	addition	of A	VCratio	improved	l significant	ly th	ıe
				· · · · · · · · · · · · · · · · · · ·							-	

- 191 models' predictive value (Net reclassification index: Whole cohort: 19.6%; p=0.01; CLF:
- 192 18.9%; p=0.05; PLF: 25.6%; p=0.03). Interestingly, there was an interaction (p=0.001)
- between AVC and AS flow pattern (i.e. CLF vs. PLF) with regard to the prediction of
- 194 mortality.
- 195 The best AVCratio threshold to predict mortality was different in CLF-AS
- 196 (AVCratio ≥ 0.7, i.e. an absolute AVC of 840 AU in female patients and 1,400AU in male
- 197 patients) and PLF-AS (AVCratio≥1, i.e. an absolute AVC of 1,200 AU in female patients
- and 2,000AU in male patients, as to define severe AS) patients. After comprehensive
- analysis, AVCratio as a dichotomic variable was associated with all-cause mortality in
- 200 the whole cohort (aHR=2.44 [1.63-3.64]; p<0.0001), as well as in CLF-AS
- 201 (AVCratio ≥ 0.7: aHR=4.01 [1.83-8.77]; p=0.001) and PLF-AS (AVCratio ≥ 1:
- 202 aHR=2.08[1.21-3.59]; p=0.008) patients (Figure 2).
- 203 Compared to background models, the addition of AVCratio as a dichotomic variable
- 204 improved significantly the models' predictive value (Net reclassification index: Whole

205 cohort: 42.9%; p<0.0001; CLF: 44.6; p=0.0002; PLF: 40.7%; p=0.001).

- 206 Impact of AVC on outcome of patients who did not undergo AVR
- Among the 181 patients who never underwent AVR (Figure 1), there were 93 deaths
- during a median follow-up of 2.7 (2.0-4.0) years. After comprehensive adjustment,
- AVCratio as a continuous variable (aHR=2.21[1.51-3.25]; p<0.0001) and AVCratio as a
- dichotomic variable (aHR=2.18[1.17-4.07]; p=0.01) were independently associated with
- 211 increased mortality (Figure 3, Panel A). Accordingly, AVCratio was independently

212 associated with inc	creased mortality in CLF-	AS patients (AVCra	atio: aHR=1.90[1.13-
-------------------------	---------------------------	--------------------	----------------------

213 3.21]; p=0.02; AVCratio≥0.7: aHR=2.75[1.11-6.82]; p=0.03), and in PLF-AS patients

214 (AVCratio: aHR=3.96[1.72-9.09]; p=0.001; AVCratio≥1: aHR=2.80[1.03-7.64]; p=0.04).

- 215 Compared to background models, the addition of AVCratio as continuous or dichotomic
- variables improved significantly the models' predictive value (whole cohort: NRI> 40%;

217 p≤0.004; CLF: NRI>65; p≤0.001; PLF: NRI>40%; p≤0.03).

#### 218 Discussion

- 219 The main findings of this study were that AVC is associated with increased mortality in
- both CLF-AS and PLF-AS patients. Interestingly, the best threshold to assess increased

221 mortality was lower (i.e. AVC≥0.7) in CLF-AS patients than in PLF-AS patients (i.e.

- AVC≥1). In all analyses, the addition of AVCratio improved the predictive value of themodel.
- 224 Since the development of sex-specific thresholds to identify severe AS, AVC

demonstrated a strong and steady association with elevated mortality in AS, which makes

226 it an important marker of AS severity. Indeed, sex-specific thresholds were associated

with severe AS as documented by concordant AVA and MG at echocardiography<sup>7, 9, 14</sup>

 $(\text{except in young bicuspid patients, especially women})^{15}$ , but they also predict overall

229 mortality<sup>8</sup> as well as mortality under medical management<sup>8</sup>, aortic valve replacement<sup>9, 10</sup>

and rapid progression of  $AS^{10}$ . The present study demonstrates that the association of

AVC with increase mortality and mortality under medical management remains in

232 patients with low flow, regardless of LVEF.

The strong association with outcome implies that AVC also may be used to determine AS
severity and timing intervention in patients with discordant AS when LVEF and/or stroke
volume are reduced.

236 Despite dobutamine stress echocardiography being the gold standard in CLF-AS patients, it may be contraindicated and 3 or unreliable in many of these patients. Moreover, we 237 238 previously demonstrated that dobutamine stress echocardiography remains inconclusive in more than 30% of patients<sup>5</sup> when using the combination of MG at peak stress  $\geq$ 40 mm 239 Hg and AVA at peak stress <1.0 cm<sup>2</sup> as proposed in the current guidelines<sup>1, 2</sup>. This low 240 241 sensitivity for identifying true-severe AS is probably the reason why the guidelines criteria were not predictive of excess mortality<sup>16</sup>. To overcome this issue, we proposed 242 the projected AVA at normal flow rate, in order to consider the patient-specific increase 243 in flow during dobutamine infusion<sup>17, 18</sup>. The projected AVA predicted was demonstrated 244 to be more accurate to identify true-severe AS than guidelines criteria, and it predicted 245 mortality in both CLF-AS and PLF-AS patients<sup>16, 18-20</sup>. However, the calculation of this 246 parameter may be prone to mistake and poorly reproducible, as it requires a steady state 247 at peak dobutamine stress to have a velocity time integral in the aorta and in the LV 248 249 outflow tract at the same stress. Unfortunately, this steady state may not always be achieved at peak stress. On the opposite, AVC is an easy, robust, and reproducible 250 251 parameter. AVC is measurable in all patients despite calcification in the aorta, the 252 coronary arteries, the mitral annulus or LV outflow tract, the presence of a pacemaker or atrial fibrillation<sup>7,9,21</sup>. All these points nevertheless have to be taken into consideration to 253 254 ensure the realization of the best scan possible (atrial fibrillation, elevated heart rate and premature ventricular beats have to be considered at the time of scanning)<sup>6</sup> and the most 255

accurate evaluation of calcification in the aortic valve (exclusion of peripheric

25/ calcification).
---------------------

258	Interestingly, the level of AVC that predicted increased mortality in CLF-AS patients was
259	in the moderate range with an AVCratio $\geq 0.7$ , which represent 70% of the severe
260	threshold, i.e. 840 AU in female patients and 1,400 AU in male patients. This finding is
261	consistent with previous studies that demonstrated that patients with low LVEF had an
262	excess mortality with a non-severe AS (i.e. a projected AVA $\leq 1.2$ cm <sup>2</sup> ) <sup>18, 19</sup> and that in
263	these patients an early intervention could be beneficial <sup>22, 23</sup> . However, in patients with
264	PLF-AS, the threshold to predict excess mortality is the same than the threshold for
265	severity. Indeed, there is no study that shows that the pathophysiology of AS could be
266	different according to flow status, thus the severity threshold of AVC to identify severe
267	AS remains AVCratio $\geq 1$ whether patients have normal flow, PLF or CLF. Thus, the
268	ventricle of patients with PLF-AS seems to be able to tolerate AS up to its severe stage.
269	At this point of severe AS, intervention should be performed if patients are symptomatic.
270	The finding that AVC impacts outcome differently depending on LVEF is paramount, as
271	it demonstrates that even milder ranges of AS may affect outcome in patients with
272	reduced LVEF. This thought provoking finding, questions the use of outcome data to
273	determine AS severity in patients with reduced LVEF.

274 Conclusion

In this large series of patients with CLF or PLF AS, AVC demonstrates to be a major
predictor of mortality. Thus, AVC should be used in low flow patients to assess AS

- severity and stratify risk. Importantly, in patients with reduced LVEF, a non-severe AS
- could be associated with reduce survival in patients with more than 70% of severe AVC.

	Whole Cohort	CLF	PLF
	N=641	N=319	N=322
Clinical data			
Age, year	77.0 ±9.8	78.1 ±9.0	75.9 ±10.5
Male Sex	429 (67%)	241 (76%)	188 (58%)
Hypertension	539 (84%)	269 (84%)	270 (84%)
Diabetes	233 (36%)	123 (39%)	110 (34%)
Coronary arteries disease	404 (63%)	237 (74%)	167 (52%)
Atrial fibrillation	272 (42%)	151 (47%)	121 (38%)
Renal failure	220 (34%)	137 (43%)	83 (26%)
NYHA functional Class			
1	68 (10%)	27 (8%)	40 (12%)
2	331 (52%)	146 (46%)	185 (57%)
3	218 (34%)	128 (40%)	90 (28%)
4	24 (4%)	18 (6%)	6 (2%)
Echocardiographic data			
Peak aortic jet, m/s	3.66 ±0.77	3.56 ±0.71	3.75 ±0.80
Mean gradient, mmHg	33.3 ±15.1	31.5 ±13.7	35.0 ±16.2
Aortic valve area, cm <sup>2</sup>	0.70 ±0.21	0.70 ±0.22	0.69 ±0.21
Stroke volume index, ml/m <sup>2</sup>	29.2 ±6.0	28.5 ±7.5	29.9 ±3.8
LV Ejection Fraction, %	47 ±16	33 ±10	61 ±6
MDCT data			
Aortic valve calcification (AU	J)		
Esmala notionta	1414	1599	1363
remaie patients	(962 – 2216)	(1003-2486)	(844-1970)
Male patients	2295	2377	2209
Wate patients	(1558-3222)	(1643-3250)	(1402-3166)
AVC ratio	1.16 (0.79-1.66)	1.20 (0.83-1.68)	1.12 (0.70-1.62)

# 280 <u>Table 1:</u> Baseline characteristic of the patients according to flow pattern

281

AVC: aortic valve calcification; LV: left ventricular; NYHA: New York Heart

283 Association

284

		CLF			PLF	
	AVCratio <0.7	AVCratio ≥0.7	p-value	AVCratio <1	AVCratio ≥1	p-value
	N=47	N=272		N=136	N=186	
Clinical data						
Age, year	75.3 ±10.6	$78.6 \pm 8.6$	0.019	73.1 ±11.6	77.9 ±9.1	< 0.001
Male Sex	38 (81%)	203 (75%)	0.36	80 (59%)	108 (58%)	0.89
Hypertension	39 (83%)	230 (85%)	0.78	114 (84%)	156 (84%)	0.99
Diabetes	20 (43%)	103 (38%)	0.54	57 (42%)	53 (28%)	0.01
Coronary arteries disease	33 (70%)	204 (75%)	0.49	62 (46%)	105 (56%)	0.05
Renal failure	23 (49%)	128 (47%)	0.81	49 (36%)	72 (39%)	0.62
Atrial fibrillation	20 (43%)	117 (43%)	0.95	30 (22%)	53 (28%)	0.19
NYHA functional class						
1	5 (11%)	22 (8%)	0.50	29 (21%)	12 (6%)	0.002
2	26 (55%)	120 (44%)		67 (49%)	118 (63%)	
3	14 (30%)	114 (42%)		37 (27%)	53 (28%)	
4	2 (4%)	16 (6%)		3 (2%)	3 (2%)	
Echocardiographic data						
Peak aortic jet, m/s	2.97 ±0.59	$3.66 \pm 0.68$	< 0.001	3.36 ±0.60	$4.04 \pm 0.82$	< 0.001
Mean gradient, mmHg	21.0 ±9.3	33.3 ±13.5	< 0.001	26.8 ±10.9	41.1 ±16.9	< 0.001
Aortic valve area, cm <sup>2</sup>	$0.89 \pm 0.26$	$0.66 \pm 0.20$	< 0.001	0.79 ±0.22	$0.62 \pm 0.16$	< 0.001
Stroke volume index, ml/m <sup>2</sup>	29.3 ±7.6	$28.4 \pm 7.4$	0.47	30.5 ±3.6	29.5 ±3.9	0.02
LV Ejection Fraction, %	36 ±10	32 ±10	0.035	61 ±6	61 ±7	0.75
MDCT data						

# **<u>Table 2:</u>** Baseline characteristic of the patients AS flow pattern and AVC threshold

Aortic valve calcification, AU						
Woman	719	1679	<0.001	759	1843	
women	(528-796)	(1151-2671)	<0.001	(470-1009)	(1494-2403)	< 0.001
Mon	1055	2553	<0.001	1304	2893	
Men	(767-1236)	(1953-3362	<0.001	(903-1674)	(2416-3841)	< 0.001
AVC ratio	0.53	1.30	<0.001	0.65	1.51	
Averano	(0.38 - 0.63)	(0.97 - 1.71)	<0.001	(0.41 - 0.84)	(1.22-1.96)	< 0.001

AVC: aortic valve calcification; LV: left ventricular; NYHA: New York Heart Association

#### **Figure legend**

#### Figure 1: Flow chart of the study

The figure shows the number of patients with low flow aortic stenosis (AS) included in the study, as well as the number of patients with decreased left ventricular ejection fraction (i.e. Classical Low Flow AS patients) and those with preserved left ventricular ejection fraction (i.e. Paradoxical Low Flow AS patients). In each subgroup, patients are divided according to management.

#### Figure 2: Cox-adjusted survival curves according to aortic valve calcification

The figure shows the Cox-adjusted survival curves according to the elevation of aortic valve calcification (AVC) in the whole cohort (Panel A), Classical Low Flow Aortic Stenosis (CLF-AS) patients (Panel B) and Paradoxical Low Flow Aortic Stenosis (PLF-AS) patients (Panel C).

In CLF-AS patients AVC is considered elevated if AVCratio  $\geq 0.7$  (i.e. the ratio of measured AVC on the sex-specific threshold identifying severe AS: 1,200 in female patients and 2,000 in male patients). In PLF-AS patients AVC is considered elevated if AVCratio  $\geq 1$ .

# **<u>Figure 3:</u>** Cox-adjusted survival curves according to aortic valve calcification in patients managed medically

The figure shows the Cox-adjusted survival curves of AS patients who never underwent aortic valve replacement, according to the elevation of aortic valve calcification (AVC) in

the whole cohort (Panel A), Classical Low Flow Aortic Stenosis (CLF-AS) patients

(Panel B) and Paradoxical Low Flow Aortic Stenosis (PLF-AS) patients (Panel C).





Figure 2 Panel A



Figure 2 Panel B





Figure 3 Panel A



Figure 3 Panel B



Figure 3 Panel C



#### References

1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, 3rd, Thompson A and Toly C. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines; executive summary. *Circulation*. 2021;143:e35-e71.

2. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C and Wojakowski W. 2021 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J*. 2022;43:561-632.

3. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, lung B, Otto CM, Pellikka PA and Quinones M. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *J Am Soc Echocardiogr*. 2009;22:1-23.

4. Clavel MA, Burwash IG and Pibarot P. Cardiac imaging for assessing low-gradient severe aortic stenosis. *JACC Cardiovasc Imaging*. 2017;10:185-202.

5. Mogensen NSB, Ali M, Carter-Storch R, Annabi MS, Grenier-Delaney J, Møller JE, Øvrehus KA, Pellikka P, Pibarot P, Clavel MA and Dahl J. Dobutamine Stress Echocardiography in Low-Gradient Aortic Stenosis. *Journal of the American society of echocardiography*. 2024.

6. Pawade T, Sheth T, Guzzetti E, Dweck MR and Clavel MA. Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis. *JACC Cardiovasc Imaging*. 2019;12:1835-1848.

7. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal S, Malouf J, Araoz P, Michelena H, Cueff C, Larose É, Capoulade R, Vahanian A and Enriquez-Sarano M. The complex nature of discordant severe calcified aortic valve disease grading: New insights from combined Doppler-echocardiographic and computed tomographic study. *J Am Coll Cardiol*. 2013;62:2329-2338.

8. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, Araoz PA, Michelena HI, Cueff C, Larose É, Miller JD, Vahanian A and Enriquez-Sarano M. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. *J Am Coll Cardiol*. 2014;64:1202-1213.

9. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, Renard C, Gun M, Jenkins WSA, Macron L, Sechrist JW, Lacomis JM, Nguyen V, Galian Gay L, Cuellar Calabria H, Ntalas I, Cartlidge TRG, Prendergast B, Rajani R, Evangelista A, Cavalcante JL, Newby DE, Pibarot P, Messika Zeitoun D and Dweck MR. Computed tomography aortic valve calcium scoring in patients with aortic stenosis. *Circ Cardiovasc Imaging*. 2018;11:e007146.

10. Tastet L, Enriquez-Sarano M, Capoulade R, Malouf J, Araoz PA, Shen M, Michelena HI, Larose É, Arsenault M, Bédard E, Pibarot P and Clavel MA. Impact of aortic valve calcification and sex on hemodynamic progression and clinical outcomes in AS. *J Am Coll Cardiol*. 2017;69:2096-2098.

11. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W and Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the European association of cardiovascular imaging. *J Am Soc Echocardiogr*. 2015;28:1-39.

12. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr. and Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol*. 1990;15:827-832.

13. Aggarwal SR, Clavel MA, Messika-Zeitoun D, Cueff C, Malouf J, Araoz PA, Mankad R, Michelena H, Vahanian A and Enriquez-Sarano M. Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis. *Circ Cardiovasc Imaging*. 2013;6:40-47.

14. Shen M, Guzzetti E, Oh JK, Singh GK, Pawade T, Tastet L, Clavel MA, Delgado V, Bax JJ, Dweck MR, Abbas AE, Mando R, Falconi ML, de Arenaza DP, Tay E, Pressman G, Brito D, Song JK and Pibarot P. Computed tomography aortic valve calcium scoring in patients with bicuspid aortic valve stenosis. *Structural Heart*. 2022;6:100027.

15. Shen M, Tastet L, Capoulade R, Larose É, Bédard É, Arsenault M, Chetaille P, Dumesnil JG, Mathieu P, Clavel MA and Pibarot P. Effect of age and aortic valve anatomy on calcification and haemodynamic severity of aortic stenosis. *Heart*. 2017;103:32-39.

16. Annabi MS, Touboul E, Dahou A, Burwash IA, Bergler-Klein J, Enriquez-Sarano M, Orwat S, Baumgartner H, Mascherbauer J, Mundigler G, Cavalcante JL, Larose É, Pibarot P and Clavel MA. Dobutamine stress echocardiography for management of low-flow, low-gradient aortic stenosis. *J Am Coll Cardiol*. 2018;71:475-85.

17. Blais C, Burwash IG, Mundigler G, Dumesnil JG, Loho N, Rader F, Baumgartner H, Beanlands RS, Chayer B, Kadem L, Garcia D, Durand LG and Pibarot P. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low flow, lowgradient aortic stenosis: The multicenter TOPAS (Truly or Pseudo Severe Aortic Stenosis) study. *Circulation*. 2006;113:711-721.

18. Clavel MA, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J, Sénéchal M, Mathieu P, Couture C, Beanlands R and Pibarot P. Validation of conventional and simplified methods to calculate projected valve area at normal flow rate in patients with low flow, low gradient aortic stenosis: the multicenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. *J Am Soc Echocardiogr.* 2010;23:380-386.

19. Clavel MA, Fuchs C, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J, Beanlands RS, Mathieu P, Magne J and Pibarot P. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. *Circulation*. 2008;118:S234-S242.

20. Clavel MA, Ennezat PV, Maréchaux S, Dumesnil JG, Capoulade R, Hachicha Z, Mathieu P, Bellouin A, Bergeron S, Meimoun P, Arsenault M, Le Tourneau T, Pasquet A, Couture C and Pibarot P. Stress echocardiography to assess stenosis severity and predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis and preserved LVEF. *J Am Coll Cardiol Img*. 2013;6:175-183.

21. Doris MK, Jenkins W, Robson P, Pawade T, Andrews JP, Bing R, Cartlidge T, Shah A, Pickering A, Williams MC, Fayad ZA, White A, van Beek EJ, Newby DE and Dweck MR. Computed tomography aortic valve calcium scoring for the assessment of aortic stenosis progression. *Heart*. 2020;106:1906-1913.

22. Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, Vollema EM, El Azzouzi I, Spitzer E, Delgado V, Bax JJ and Clavel MA. Moderate aortic stenosis in patients with heart failure and reduced ejection fraction. *J Am Coll Cardiol*. 2021;77:2796-803.

23. Ludwig S, Schofer N, Abdel-Wahab M, Urena M, Jean G, Renker M, Hamm CW, Thiele H, lung B, Ooms JF, Wiessman M, Mogensen NSB, Longère B, Perrin N, Ben Ali W, Coisne A, Dahl JS, Van Mieghem NM, Kornowski R, Kim WK and Clavel MA. Transcatheter aortic valve replacement in patients with reduced ejection fraction and nonsevere aortic stenosis. *Circ Cardiovasc Interv*. 2023;16:e012768.